Overview

Neoadjuvant Sunitinib With Paclitaxel/Carboplatin in Patients With Triple-Negative Breast Cancer

Status:
Completed
Trial end date:
2014-09-01
Target enrollment:
Participant gender:
Summary
This trial will examine the combination of sunitinib plus paclitaxel and carboplatin as neoadjuvant treatment for locally advanced breast cancer.
Phase:
Phase 1/Phase 2
Details
Lead Sponsor:
SCRI Development Innovations, LLC
Collaborator:
Pfizer
Treatments:
Albumin-Bound Paclitaxel
Carboplatin
Paclitaxel
Sunitinib